COLL — Collegium Pharmaceutical Inc

Collegium Pharmaceutical Inc (COLL) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Vikram Karnani, based in 100 Technology Center Drive, Stoughton, MA, United States, 02072, with about 423 employees. Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Latest reported COLL revenue for 2025-09-30 was $209.4M. Net income was $45.9M. Revenue was up 11.4% from 2025-06-30 to 2025-09-30. COLL currently screens at market cap $1.12B and trailing P/E 16.8.

Use this COLL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the COLL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the COLL SEC filings page. Lician reads the product cache first so this HTML stays unique to Collegium Pharmaceutical Inc even when a live quote feed is slow.